Dr. Terence W. Friedlander, MS
Hematology & Oncology (Hematology & Oncology Physician)
505 Parnassus Ave Moffitt M1286 Mail Stop 1270, Ucsf Medical Center
San Francisco, CA 94143
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 122
Licensed in California since 2004, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: New York University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A88888 (first issued 2004; current) -
Internal Medicine Physician
CA license A88888 (first issued 2004; current) -
Medical Oncology Physician
CA license A88888 (first issued 2004; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
- Zuckerberg San Francisco General Hosp & Trauma Ctr San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
- University of California Sfgh Medical Group (587 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 122
- Services billed
- 6,845
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 157 | 85 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 31 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 56 |
| Xtandi (enzalutamide) | 51 |
| Prednisone Other prescribers in San Francisco, CA | 28 |
| Lamivudine Hbv (lamivudine) | 24 |
| Oxycodone Hcl Other prescribers in San Francisco, CA | 24 |
| Dexamethasone Other prescribers in San Francisco, CA | 18 |
| Ondansetron Hcl Other prescribers in San Francisco, CA | 16 |
| Tamsulosin Hcl Other prescribers in San Francisco, CA | 16 |
| Pantoprazole Sodium Other prescribers in San Francisco, CA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 28 payments worth $36,762 in total to this clinician.
| Merck Sharp & Dohme LLC | $11,696 |
|---|---|
| Samsung Bioepis Co., LTD. | $8,385 |
| Astellas Pharma US Inc | $4,600 |
| Astellas Pharma Europe LTD | $3,479 |
| Merck Kgaa | $3,195 |
| EMD Serono Research & Development Institute, Inc. | $3,195 |
| Hexal AG | $1,600 |
| Pfizer Inc. | $342 |
| Consulting Fee | $23,035 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $10,875 |
| Travel and Lodging | $2,043 |
| Food and Beverage | $809 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Astellas Pharma US Inc Oct 20, 2025 | Consulting Fee Padcev · Oncology | $4,600 |
| Astellas Pharma Europe LTD Apr 7, 2025 | Consulting Fee Padcev · Oncology | $3,400 |
| EMD Serono Research & Development Institute, Inc. Jul 14, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $3,195 |
| Merck Kgaa Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $3,195 |
| Samsung Bioepis Co., LTD. Jul 3, 2025 | Consulting Fee E303 · Hematology | $3,120 |
| Samsung Bioepis Co., LTD. Jul 24, 2025 | Consulting Fee E303 · Hematology | $3,120 |
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $1,920 |
| Hexal AG Nov 24, 2025 | Consulting Fee | $1,600 |
| Samsung Bioepis Co., LTD. Apr 24, 2025 | Consulting Fee E303 · Hematology | $1,040 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 1, 2025 | Consulting Fee | $1,920 |
| Hexal AG Nov 24, 2025 | Consulting Fee | $1,600 |
| Astellas Pharma US Inc Oct 20, 2025 | Consulting Fee Padcev · Oncology | $4,600 |
| Astellas Pharma Europe LTD Oct 20, 2025 | Travel and Lodging Vyloy · Oncology · travel to Berlin, Germany | $17.90 |
| Samsung Bioepis Co., LTD. Sep 25, 2025 | Consulting Fee E303 · Hematology | $1,040 |
| Merck Sharp & Dohme LLC Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $7,680 |
| Merck Sharp & Dohme LLC Aug 27, 2025 | Travel and Lodging travel to Taipei, Taiwan | $150 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Travel and Lodging travel to Taipei, Taiwan · in-kind | $930 |
| Merck Sharp & Dohme LLC Aug 15, 2025 | Travel and Lodging travel to Taipei, Taiwan · in-kind | $274 |
| Merck Sharp & Dohme LLC Aug 14, 2025 | Travel and Lodging travel to Taipei, Taiwan · in-kind | $274 |
| Merck Sharp & Dohme LLC Aug 14, 2025 | Travel and Lodging travel to Taipei, Taiwan · in-kind | $123 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Travel and Lodging travel to Taipei, Taiwan · in-kind | $274 |
| Samsung Bioepis Co., LTD. Jul 24, 2025 | Consulting Fee E303 · Hematology | $3,120 |
| EMD Serono Research & Development Institute, Inc. Jul 14, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $3,195 |
| Samsung Bioepis Co., LTD. Jul 3, 2025 | Consulting Fee E303 · Hematology | $3,120 |
| Samsung Bioepis Co., LTD. Apr 24, 2025 | Consulting Fee E303 · Hematology | $1,040 |
| Astellas Pharma Europe LTD Apr 7, 2025 | Consulting Fee Padcev · Oncology | $3,400 |
| Merck Kgaa Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaking Services (Fee For Service) | $3,195 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $293,833 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - Morpheus UC
Roche Products Limited - Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
AbbVie Inc. · Active, not recruiting · NCT06632951 - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.